# Legend Biotech presents first-in-human Phase 1 data for LB2501 in vivo CAR-T therapy at EHA 2026

_Thursday, June 25, 2026 at 8:07 PM EDT · science · Latest · Tier 2 — Notable_

![Legend Biotech presents first-in-human Phase 1 data for LB2501 in vivo CAR-T therapy at EHA 2026 — Primary](https://static.biospace.com/dims4/default/d32393a/2147483647/strip/true/crop/1120x630+40+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Fcc%2F88%2Fa9fddaf440db946b77e1d45d2e26%2Fbiospace-5.png)

Legend Biotech Corporation announced preliminary clinical data for its investigational LB2501 therapy. The data will be presented during a late-breaking session at the European Hematology Association 2026 Congress in Stockholm, Sweden.

The Phase 1 study evaluated LB2501 in 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma across two dose levels. At dose level 2, the objective response rate reached 100 percent in six patients, including a complete response rate of 83.3 percent. All responses were ongoing at data cutoff as of April 1, 2026.

CAR-T cells showed dose-dependent expansion and remained detectable in peripheral blood for up to 116 days. The therapy generated these cells directly in patients after a single infusion without requiring cell manufacturing or lymphodepleting chemotherapy.

No dose-limiting toxicities, serious adverse events, or deaths were reported. Infusion-related reactions occurred in 75 percent of patients, all Grade 2 or lower. Cytokine release syndrome affected 66.7 percent of patients but stayed at Grade 2 or lower, and no immune effector cell-associated neurotoxicity syndrome occurred.

LB2501 is a CD19/CD20 dual-targeting in vivo CAR-T therapy built on the TaVec platform. It is under evaluation in an ongoing Phase 1, open-label study for safety, tolerability, and preliminary efficacy in patients with relapsed or refractory B-cell malignancies.

## Sources

- [BioSpace](https://www.biospace.com/press-releases/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl)

---
Canonical: https://techandbusiness.org/newswire/WMYow9Ig064KslncDKMvd8
Retrieved: 2026-06-26T04:36:55.470Z
Publisher: Tech & Business (techandbusiness.org)